Lani HackEngineer II, ASO Formulation Development and Manufacturing at Biogen
Lani Hack has been an engineer in the Antisense Oligonucleotide Formulation Development and Manufacturing group at Biogen since 2017. Her primary responsibilities are on the drug product development team, where she is responsible for the development of candidate therapeutic molecules within the antisense oligonucleotide pipeline, from early stage clinical trials through commercial life cycle management. Lani is also a member of the drug delivery team, directing the assessment of new delivery technologies to enhance the efficacy of oligonucleotide therapeutics for neurological indications. This work is driven through internal technical development initiatives and external collaborations. She is also responsible for developing novel biophysical characterization methods to assess physicochemical properties of oligonucleotides.
Lani holds a bachelor’s degree in Chemical Engineering from the University of California, Berkeley.